{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:50:10Z","timestamp":1793137810616,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The treatment of primary Sj\u00f6gren\u2019s syndrome (pSS) coexisting with neuromyelitis optica spectrum disorder (NMOSD) using protein-A immunoadsorption combined with immunosuppressive therapy has rarely been reported. Herein, we present the case of a 35-year-old female diagnosed with pSS concomitant with NMOSD (pSS-NMOSD) who demonstrated a positive response to protein-A immunoadsorption after failing to respond to therapy comprising high-dose intravenous methylprednisolone (IVMP) and intravenous immunoglobulin (IVIG). Within one week of receiving three sessions of immunoadsorption combined with immunosuppressive treatment, the patient\u2019s clinical symptoms (blurred vision, paraparesis, and dysfunctional proprioception) significantly improved. Additionally, a rapid decrease in the circulating levels of Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), immunoglobulin (Ig) A, IgG, IgM, erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) were observed. Magnetic resonance imaging (MRI) further revealed a significant reduction in the lesions associated with longitudinal extensive transverse myelitis. During the follow-up period, prednisolone was gradually tapered to a maintenance dose of 5-10 mg\/day, whereas mycophenolate mofetil (MMF) was maintained at 1.0-1.5 g\/day. The patient\u2019s condition has remained stable for four years, with no signs of recurrence or progression observed on imaging examination. Therefore, this case suggests that protein A immunoadsorption may represent a potentially effective therapeutic option for patients with pSS-NMOSD who are refractory to conventional treatments.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1429405","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:42:05Z","timestamp":1720672925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Protein-A immunoadsorption combined with immunosuppressive treatment in refractory primary Sj\u00f6gren\u2019s syndrome coexisting with NMOSD: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Wei","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","article-title":"Genetics and epigenetics of primary Sj\u00f6gren syndrome: implications for future therapies","volume":"19","author":"Thorlacius","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06448-w","article-title":"Clinical features and high-risk indicators of central nervous system involvement in primary Sj\u00f6gren\u2019s syndrome","volume":"42","author":"Fan","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum Disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.lanwpc.2020.100021","article-title":"Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study","volume":"2","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05397-0","article-title":"Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sj\u00f6gren\u2019s syndrome: a systematic review of individual patient data","author":"Prasad","year":"2023","journal-title":"Rheumatol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000179","article-title":"Epidemiology of neurological manifestations in Sj\u00f6gren\u2019s syndrome: data from the French ASSESS Cohort","volume":"2","author":"Carvajal Alegria","year":"2016","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.09.015","article-title":"Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations","volume":"18","author":"Sahraian","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650782","article-title":"Dynamic changes in AQP4-igG level and immunological markers during protein-A immunoadsorption therapy for NMOSD: A case report and literature review","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10377-6","article-title":"Impact of comorbid Sj\u00f6gren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"268","author":"Akaishi","year":"2021","journal-title":"J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02527","article-title":"Serum clusterin and complement factor H may be biomarkers differentiate primary Sj\u00f6gren\u2019s syndrome with and without neuromyelitis optica spectrum disorder","volume":"10","author":"Qiao","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.05.005","article-title":"Neuromyelitis optica spectrum disorder as an initial presentation of primary Sj\u00f6gren\u2019s syndrome","volume":"40","author":"Kahlenberg","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e6388","DOI":"10.5867\/medwave.2016.01.6388","article-title":"Neuromyelitis optica spectrum disorders as initial presentation of Sj\u00f6gren\u2019s syndrome: A case report","volume":"16","author":"Alva D\u00edaz","year":"2016","journal-title":"Medwave"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23107","article-title":"Relationship between neuromyelitis optica spectrum disorder and Sj\u00f6gren\u2019s syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity","volume":"69","author":"Birnbaum","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12883-014-0200-5","article-title":"Sj\u00f6gren\u2019s syndrome and neuromyelitis optica spectrum disorders (NMOSD)\u2013a case report and review of literature","volume":"14","author":"Jayarangaiah","year":"2014","journal-title":"BMC Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report","volume":"26","author":"Komai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2011.7.3.115","article-title":"New insights into neuromyelitis optica","volume":"7","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011486","article-title":"Longlasting effects of immunoadsorption in severe Sj\u00f6gren\u2019s syndrome","volume":"63","author":"B\u00f6hm","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0101-4","article-title":"Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen","volume":"26","author":"Claus","year":"2006","journal-title":"Rheumatol Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10047-018-1044-3","article-title":"Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level","volume":"21","author":"Nishimura","year":"2018","journal-title":"J Artif Organs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17562864221150314","DOI":"10.1177\/17562864221150314","article-title":"Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder","volume":"16","author":"Heigl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.msard.2019.101480","article-title":"HA280 immunoadsorption, an alternative treatment for neuromyelitis optica spectrum disorders","volume":"37","author":"Liu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21965","article-title":"A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders","volume":"37","author":"Liu","year":"2022","journal-title":"J Clin Apher"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616646332","article-title":"Immunoadsorption in patients with neuromyelitis optica spectrum disorder","volume":"9","author":"Faissner","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12974-016-0767-4","article-title":"Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica","volume":"13","author":"Liu","year":"2016","journal-title":"J Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1429405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:42:09Z","timestamp":1720672929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1429405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2024.1429405"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1429405","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"article-number":"1429405"}}